Last reviewed 2026-06-02 · How we verify

Deracyn (ADINAZOLAM)

Phase 2 active Small molecule ✓ Verified Jun 2026

Deracyn (generic name: ADINAZOLAM) is a adinazolam drug. It is currently in Phase 2 development for Anxiety.

Deracyn works by binding to the translocator protein, which is involved in regulating the activity of GABA, a neurotransmitter that helps calm the brain.

Deracyn is a small molecule modality. It is also known by the synonyms ADINAZOLAM MESILATE, ADINAZOLAM MESYLATE, ADINAZOLAM MESYLATE, ADINAZOLAM METHANESULFONATE, ADINAZOLAM METHANESULFONATE, and U-41,123F.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ADINAZOLAM
Drug class	adinazolam
Target	Translocator protein
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Think of it like a key fitting into a lock. Deracyn binds to the translocator protein, which helps to increase the activity of GABA, a chemical messenger that helps to calm the brain and reduce anxiety. This can lead to a sense of relaxation and reduced worry.

Approved indications

Anxiety

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Deracyn CI brief — competitive landscape report
Deracyn updates RSS · CI watch RSS

Frequently asked questions about Deracyn

What is Deracyn?

Deracyn (ADINAZOLAM) is a adinazolam drug, indicated for Anxiety.

How does Deracyn work?

Deracyn works by binding to the translocator protein, which is involved in regulating the activity of GABA, a neurotransmitter that helps calm the brain.

What is Deracyn used for?

Deracyn is indicated for Anxiety.

What is the generic name of Deracyn?

ADINAZOLAM is the generic (nonproprietary) name of Deracyn.

What drug class is Deracyn in?

Deracyn belongs to the adinazolam class. See all adinazolam drugs at /class/adinazolam.

What development phase is Deracyn in?

Deracyn is in Phase 2.

What does Deracyn target?

Deracyn targets Translocator protein and is a adinazolam.

Drug class: All adinazolam drugs
Target: All drugs targeting Translocator protein
Therapeutic area: All drugs in Neuroscience
Indication: Drugs for Anxiety

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing